Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England.

Ben Rothwell Christopher Kiff Caroline LingThor-Henrik Brodtkorb

Published in: PharmacoEconomics - open (2020)

Nivolumab versus docetaxel is cost effective for treating locally advanced/metastatic NSCLC after prior chemotherapy in adults, regardless of tumour histology or programmed death-ligand 1 expression status.

Keyphrases

locally advanced
squamous cell carcinoma
high grade
small cell lung cancer
rectal cancer
neoadjuvant chemotherapy
low grade
phase ii study
radiation therapy
poor prognosis
advanced non small cell lung cancer
binding protein
brain metastases
clinical trial
newly diagnosed